Brooke Daniel

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

Véronique Dièras, Robert Weaver, Sara M. Tolaney et al. · Cancer Research · 2021 · 60 citations

Breast Oncology, Immunology, Immunotherapeutics +20

Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial

Denise A. Yardley, Patrick J. Ward, Brooke Daniel et al. · Clinical Breast Cancer · 2016 · 44 citations

Breast Oncology, Medicine, Breast Cancer +4

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Denise A. Yardley, James A. Reeves, Elizabeth Claire Dees et al. · Clinical Breast Cancer · 2016 · 32 citations

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Denise A. Yardley, Edward Arrowsmith, Brooke Daniel et al. · Breast Cancer Research and Treatment · 2017 · 27 citations

Breast Oncology, Medicine, Pharmacology +6